BiotechTube

CS-3150

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertension With Moderate Renal Impairment

Conditions

Hypertension With Moderate Renal Impairment

Trial Timeline

Jun 1, 2016 → May 15, 2017

NCT ID
NCT02807987

About CS-3150

CS-3150 is a phase 3 stage product being developed by Daiichi Sankyo for Hypertension With Moderate Renal Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT02807987. Target conditions include Hypertension With Moderate Renal Impairment.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (6)

NCT IDPhaseStatus
NCT02885662Pre-clinicalCompleted
NCT02807974Phase 3Completed
NCT02808026Phase 3Completed
NCT02807987Phase 3Completed
NCT02722265Phase 3Completed
NCT02448628Phase 2Completed

Competing Products

20 competing products in Hypertension With Moderate Renal Impairment

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
76
tadalafil + tadalafilEli LillyPhase 3
77
CS1 AdministrationCereno ScientificPhase 2
47
CS1Cereno ScientificPre-clinical
18
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
44
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
44
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
85
L04RD1 + L04TD3CelltrionPhase 1
33
Azilsartan MedoxomilCelltrionPre-clinical
23
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mgCelltrionPhase 3
77
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
52
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
85
Telmisartan + Amlodipine + ChlorthalidoneYuhanPhase 1
33
Temisartan/Amlodipine+Rosuvastatin + YHP1604YuhanPhase 1
33
Temisartan+Amlodipine+Rosuvastatin (Combination drug) + Temisartan+Amlodipine + Temisartan+RosuvastatinYuhanPhase 3
77
Amlodipine + ValsartanYuhanApproved
85
Duowell® + TelmisartanYuhanApproved
85
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
77
YH22189 + Twynsta 80/10mg + Crestor 20mgYuhanPhase 1
33
OM 40 + OM/HCTZ 40/12.5Daiichi SankyoPhase 3
77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85